CONMED Corporation logo

CONMED Corporation

CNMD

NYSEHealthcareMedical - Devices

Previous close

$51.07

−$0.31 · -0.60%

Aug 21, 4:00 PM ET

Pre-market

$51.07

$0.00 · 0.00%

Aug 24, 5:25 AM ET

CNMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

81

Deep Value

Momentum

59

Neutral

Sentiment

62

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Patrick J. Beyer
Listed since
Jul 23, 1987
Employees
3,900

Market position

Day range

Current $51.07

52-week range

Current $51.07

Open
$51.03
Previous close
$51.38
Volume
183.95K
0.33× average
Average volume
565.01K
Average daily volume
Market cap
1.53B USD
Beta
0.9
Market reference 1
50-day average
$41.7758
+22.25% above average
200-day average
$40.1882
+27.08% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.05B USD
EV / EBITDA
13.29×
Earnings yield
3.73%
Free cash flow yield
11.97%

Profitability & efficiency

Return on equity
4.55%
Return on assets
2.02%
Return on invested capital
4.64%

Financial health

Current ratio
2.14×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends63%37%11%-14%Gross margin, FY2021: 56.21%Gross margin, FY2022: 54.64%Gross margin, FY2023: 54.33%Gross margin, FY2024: 56.08%Gross margin, FY2025: 52.77%Operating margin, FY2021: 10.86%Operating margin, FY2022: 6.70%Operating margin, FY2023: 9.69%Operating margin, FY2024: 15.33%Operating margin, FY2025: 10.27%Net margin, FY2021: 6.19%Net margin, FY2022: -7.71%Net margin, FY2023: 5.18%Net margin, FY2024: 10.13%Net margin, FY2025: 3.42%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.21%. Gross margin FY2022 54.64%. Gross margin FY2023 54.33%. Gross margin FY2024 56.08%. Gross margin FY2025 52.77%. Operating margin FY2021 10.86%. Operating margin FY2022 6.70%. Operating margin FY2023 9.69%. Operating margin FY2024 15.33%. Operating margin FY2025 10.27%. Net margin FY2021 6.19%. Net margin FY2022 -7.71%. Net margin FY2023 5.18%. Net margin FY2024 10.13%. Net margin FY2025 3.42%.

Income trends

Revenue

1.37B USD+5.16%

Operating income

141.13M USD-29.55%

Net income

47.06M USD-64.47%
Income trends across reported periods1.52B USD937.97M USD355.94M USD−226.09M USDRevenue, FY2021: 1.01B USDRevenue, FY2022: 1.05B USDRevenue, FY2023: 1.24B USDRevenue, FY2024: 1.31B USDRevenue, FY2025: 1.37B USDOperating income, FY2021: 109.72M USDOperating income, FY2022: 70.05M USDOperating income, FY2023: 120.6M USDOperating income, FY2024: 200.33M USDOperating income, FY2025: 141.13M USDNet income, FY2021: 62.54M USDNet income, FY2022: −80.58M USDNet income, FY2023: 64.46M USDNet income, FY2024: 132.42M USDNet income, FY2025: 47.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.01B USD. Revenue FY2022 1.05B USD. Revenue FY2023 1.24B USD. Revenue FY2024 1.31B USD. Revenue FY2025 1.37B USD. Operating income FY2021 109.72M USD. Operating income FY2022 70.05M USD. Operating income FY2023 120.6M USD. Operating income FY2024 200.33M USD. Operating income FY2025 141.13M USD. Net income FY2021 62.54M USD. Net income FY2022 −80.58M USD. Net income FY2023 64.46M USD. Net income FY2024 132.42M USD. Net income FY2025 47.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.37B USD1.31B USD1.24B USD1.05B USD1.01B USD
Cost of goods sold649.12M USD573.98M USD568.5M USD474.23M USD442.6M USD
Gross profit725.38M USD733.03M USD676.25M USD571.25M USD568.04M USD
Research and development55.88M USD54.43M USD52.6M USD47.15M USD43.57M USD
Selling, general, and administrative528.36M USD478.28M USD503.04M USD454.04M USD414.75M USD
Operating expenses584.24M USD532.71M USD555.64M USD501.19M USD458.32M USD
Interest expense31.09M USD37.3M USD39.78M USD28.91M USD35.49M USD
Depreciation and amortization52.34M USD71.86M USD71.87M USD49.76M USD70.74M USD
Operating income141.13M USD200.33M USD120.6M USD70.05M USD109.72M USD
Net income47.06M USD132.42M USD64.46M USD−80.58M USD62.54M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+8.25%
11 comparable reports
Latest EPS result
1.38
Estimate 1.11 · Beat by 24.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.491.2410.75Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 1.34, estimate 1.2, surprise +11.67%, Beat. Q2 2025, reported Apr 30, 2025: actual 0.95, estimate 0.81, surprise +17.28%, Beat. Q3 2025, reported Jul 30, 2025: actual 1.15, estimate 1.13, surprise +1.77%, Beat. Q4 2025, reported Nov 5, 2025: actual 1.08, estimate 1.05, surprise +2.86%, Beat. Q1 2026, reported Jan 28, 2026: actual 1.43, estimate 1.32, surprise +8.33%, Beat. Q2 2026, reported Apr 29, 2026: actual 0.89, estimate 0.82, surprise +8.54%, Beat. Q3 2026, reported Jul 29, 2026: actual 1.38, estimate 1.11, surprise +24.32%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates388.13M357.32M326.52M295.71MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 347.93M USD, estimate 341.05M USD, surprise +2.02%, Beat. Q2 2025, reported Apr 30, 2025: actual 321.26M USD, estimate 313.38M USD, surprise +2.51%, Beat. Q3 2025, reported Jul 30, 2025: actual 342.35M USD, estimate 334.6M USD, surprise +2.32%, Beat. Q4 2025, reported Nov 5, 2025: actual 337.93M USD, estimate 366.88M USD, surprise -7.89%, Miss. Q1 2026, reported Jan 28, 2026: actual 373.2M USD, estimate 366.88M USD, surprise +1.72%, Beat. Q2 2026, reported Apr 29, 2026: actual 317.05M USD, estimate 310.64M USD, surprise +2.06%, Beat. Q3 2026, reported Jul 29, 2026: actual 343.49M USD, estimate 337.6M USD, surprise +1.75%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 336.25M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$37.50

26.57% downside
Past 12 months12-month forecastHigh $39.00Average $37.50Low $36.00

Rating distribution

21 ratings
Strong buy00%
Buy733%
Hold1362%
Sell15%
Strong sell00%

CNMD news

Corporate actions

Corporate action history

Stock split

Effective Sep 10, 2001

3:2

Stock split

Effective Dec 1, 1995

3:2

Stock split

Effective Dec 28, 1994

3:2

CNMD peers

ETFs holding CNMD

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CNMD

research.disclaimer